OpenEvidence vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
OpenEvidence hit $100M+ ARR in under a year serving 430K+ US physicians (40% of all US doctors) at $12B valuation ($700M raised); fastest-growing physician AI platform, founded 2022 Miami.
About
OpenEvidence is an AI clinical evidence platform founded in 2022 and headquartered in Miami, Florida. Built specifically for physicians, the platform applies large language models trained on peer-reviewed medical literature to deliver instant, evidence-backed answers to clinical questions at the point of care. Its founding mission is to democratize access to the best available medical evidence so that every physician can practice at the highest standard, regardless of institution or specialty.\n\nThe platform aggregates and synthesizes peer-reviewed studies, clinical guidelines, and drug databases, presenting structured answers with citations that meet physician-grade accuracy standards. Unlike general-purpose AI assistants, OpenEvidence is purpose-built for clinical workflows. It is free to use for physicians, with monetization routed through pharmaceutical and healthcare industry partners who value the platform's direct access to practicing clinicians.\n\nOpenEvidence has achieved remarkable traction, reaching over 430,000 US physicians — approximately 40% of the entire US physician population — making it the fastest-growing physician AI platform on record. The company crossed $100M ARR in under a year from launch and earned a $12 billion valuation on $700 million in total funding. This trajectory places OpenEvidence among the fastest-scaling healthcare AI companies globally and signals a structural shift toward AI-assisted clinical decision-making at the point of care.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.